Daikos G K
Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S831-5. doi: 10.1093/clinids/7.supplement_4.s831.
Aztreonam is a new, synthetic, monobactam beta-lactam antibiotic with activity directed specifically against aerobic gram-negative bacteria. At doses of 1-8 g per day, aztreonam was administered parenterally to patients with serious gram-negative infections of the urinary tract or other sites. A total of 462 organisms were isolated from sites of urinary tract infection; 93% of the isolates obtained within 48 hr before the initiation of aztreonam therapy were eradicated. Forty-three (86%) of 50 strains of Pseudomonas aeruginosa from urinary sites were eradicated. Eighty-six percent of gram-negative organisms isolated before treatment from other sites of infection were eradicated. Whatever the site of infection, the percentage of patients with a complete resolution of signs and symptoms was similar. Aztreonam was well tolerated both locally and systemically.
氨曲南是一种新型的合成单环β-内酰胺抗生素，其活性专门针对需氧革兰氏阴性菌。每天以1 - 8克的剂量，对患有严重泌尿系统或其他部位革兰氏阴性感染的患者进行肠胃外给药。总共从尿路感染部位分离出462种微生物；在开始氨曲南治疗前48小时内分离出的菌株中，93%被根除。来自泌尿部位的50株铜绿假单胞菌中有43株（86%）被根除。治疗前从其他感染部位分离出的革兰氏阴性菌中有86%被根除。无论感染部位如何，体征和症状完全消退的患者百分比相似。氨曲南在局部和全身都具有良好的耐受性。
